BOSTON & PFAFFIKON, Switzerland—Itarcia Therapeutics Inc., together with Numab Therapeutics AG, shared news recently that the companies’ development partnership had reached its first key milestone by selecting a multispecific antibody construct targeting autoimmune and inflammatory diseases. The milestone triggers a payment to Numab that brings total payments for the deal to date to CHF 11.5 million.

“Intarcia is excited to take this next step in our autoimmune and inflammatory disease programs with Numab,” Kurt Graves, chairman, president and CEO of Intarcia, said in a press release. “We’re committed to spearheading disruptive innovation by leveraging our proprietary Medici Drug Delivery System. With this new milestone in our partnership, we now have several combination products in our pipeline that we believe can be uniquely optimized for delivery in our Medici system.”